Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Prospective Study of FVD Program and HD-MTX-Ara-C Program Contrast in the Treatment of PCNSL Lymphoma.

NCT01960192 is registered in ClinicalTrials.gov with Mingzhi Zhang as lead sponsor.

NCT NCT01960192
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01960192 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Prospective Study of FVD Program and HD-MTX-Ara-C Program Contrast in the Treatment of PCNSL Lymphoma.
Lead sponsor
Mingzhi Zhang
Phase
Phase 4
Overall status
Unknown status
Start date
June 30, 2012
Completion date
June 30, 2020
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary cns lymphoma (pcnsl)